Modeling of 82 brand drugs with ≥$100 million Medicaid spend found net prices exceeded at least one international reference ...

A rebate-driven formulary model allegedly incentivized higher insulin list prices, affecting three PBMs controlling roughly ...

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...

A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...

This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited ...

In the second and final part of her interview with The American Journal of Managed Care ® (AJMC ®), Cherie Daly, MD, director ...

The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...

Propensity-matched comparisons across 11 Kaiser Permanente Southern California service areas showed similar 30-day composite ...

Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease. One example of this new era is the SURPASS-CVOT trial (NCT04255433), a ...

Restricting step-up dosing and acute triage to a defined T-cell engaging team improves safety and consistency, with patients transitioning back to primary oncologists after stabilization. Standardized ...

Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains. When high-efficacy drugs stop holding relapsing ...